knowledge -WSS

knowledge

author：leisure time 2025-09-29 19:06:14 - browse：41497

The Food and Drug Administration on Tuesday approved brexanolone, the first drug specifically targeted to treat postpartum depression — the most common complication of childbirth. Yet it’s a condition that often goes untreated because new mothers fear being stigmatized if they report symptoms.

Brexanolone is the first drug developed by and approved from Sage Therapeutics. The Cambridge, Mass.-based biotech company will market the new medicine under the brand name Zulresso.

“This approval is important for postpartum depression patients and it’s important for our company. It’s rare in your career when you can introduce a new medicine that is different from what’s out there,” said Sage CEO Jeff Jonas.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： SEC charges former device maker CEO with $41 million fraud

WSS

Virtual care provider acquires bankrupt Pear's prescription apps

Listen: Biogen's potential pivot, & Illumina's next chapter

Medicare drug price negotiation hasn't dried up venture capital

Illumina names Agilent executive as new CEO

Covid hospitalizations on the rise, Humana says

NIH nominee Bertagnolli will get October confirmation hearing

explore

knowledge

focus

ChatGPT in medicine: STAT answers readers' burning questions

How to protect patients from sexual assault

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Illumina names Agilent executive as new CEO

BioMarin wins approval for gene therapy to treat hemophilia A

How to fix cancer clinical trials' diversity problem

Novavax promises a turnaround & Lilly roils the obesity market

Drinking less cuts risk of oral cavity, esophageal cancer: Report

Supreme Court strikes down use of affirmative action

SEC charges former device maker CEO with $41 million fraud

explore

SEC charges former device maker CEO with $41 million fraud

ALS advocates say criticism of new drugs misses bigger picture

SNAP should offer more nutrition education

Virtual care provider acquires bankrupt Pear's prescription apps

Violet CEO on training clinicians to promote more inclusive care

Why Novartis is changing the name of its research labs

knowledge

entertainment

leisure time

leisure time